Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/17/2025

Treatment of Complicated Urinary Tract Infections in Prostate Cancer Patients

Classification and Considerations

  • The European Urology guidelines recognize male gender and presence of cancer as complicating factors in urinary tract infections, classifying this as a complicated urinary tract infection (cUTI) 1, 3
  • Klebsiella species, including K. aerogenes, are common uropathogens in complicated UTIs and may demonstrate increased antimicrobial resistance compared to pathogens in uncomplicated infections 2

Antibiotic Selection Algorithm

  • The European Urology guidelines recommend obtaining urine culture and susceptibility testing before initiating therapy to guide targeted treatment 1
  • Initial empiric therapy options include combination therapy with amoxicillin plus an aminoglycoside 1, second-generation cephalosporin plus an aminoglycoside 3, or intravenous third-generation cephalosporin 2
  • Once susceptibility results are available, therapy should be tailored to the specific antibiotic susceptibility pattern of the isolated K. aerogenes 1

Treatment Duration

  • A 14-day course of antibiotic therapy is recommended for male patients with prostate cancer and urinary tract infection caused by Klebsiella aerogenes, as prostatitis cannot be excluded in this clinical scenario 1, 2
  • This longer duration is critical for male patients with UTI to ensure complete eradication of the infection and prevent recurrence 3

Monitoring and Follow-up

  • Clinical improvement is expected within 48-72 hours of initiating appropriate antibiotic therapy, and monitoring is recommended 2
  • If fever persists beyond 72 hours or clinical status deteriorates, additional imaging should be considered to rule out complications 4
  • Surveillance urine cultures after treatment completion should be avoided if the patient becomes asymptomatic 5

Pitfalls to Avoid

  • Fluoroquinolones should not be used for empiric treatment if the patient has been exposed to this class in the previous 6 months or if local resistance rates exceed 10% 1
  • Treatment duration should not be less than 14 days in male patients with prostate cancer, as this increases risk of treatment failure and recurrence 1, 2
  • Routine post-treatment urine cultures should not be performed in asymptomatic patients, as asymptomatic bacteriuria should not be treated 5